Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
SEATTLE, Dec. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.(CTI)
(Nasdaq and MTA: CTIC) announced today they have closed the transaction with
Spectrum Pharmaceuticals, Inc. to form a 50/50 owned joint venture, RIT
Oncology LLC (LLC), to commercialize and develop Zevalin(R) ([90Y]-ibritumoma...
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
SEATTLE, Dec. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) announced today that the results of three Italian
multicenter studies utilizing Zevalin(R) ([90Y]-ibritumomab tiuxetan) were
presented at the American Society of Hematology (ASH) 50th Annual Meeting in
FDA Approves Anti-Cancer Cell Drug - Zevalin
The government approved a long-awaited treatment for lymphoma - a drug that uses a novel approach to bring radiation directly to cancer cells. Idec Pharmaceuticals' Zevalin
becomes the first radioimmunotherapy drug cleared to sell in the US. //
It's a new approach, adding radiation to antibod...
Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
...s, Inc. associated with the initial divestiture of zevalin
to the joint venture with Spectrum and the subsequ... one-time gain on the sale CTI's investment in the zevalin
joint venture coupled with a decrease in research ...penses and gain on sale of CTI's investment in the zevalin
CTI had approximately $0.7 mil...
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
...onstrating that rituximab followed by single agent zevalin
tiuxetan) in a front-line setting for...erefore, systemic targeted radioimmunotherapy with zevalin
might offer an
alternative to treating OAL.
"This study demonstrates the potential for zevalin
to provide an
alternative to EBRT, the current sta...
Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
...al Biologics License Application (sBLA) for use of zevalin
as consolidation therapy in patients with follicul...A in early April, 2009.
(R) (Ibritumomab Tiuxetan) is a form of cancer th...radioimmunotherapy and is indicated as part of the zevalin
therapeutic regimen for treatment of relapsed or r...
Zevalin Data to be Presented at ASH 2008
...ectrum announced on November 26, 2008 that they have entered
into an agreement to form a joint venture, RIT Oncology LLC, to commercialize
and develop zevalin
in the United States.
Date/Time Abstract # Poster # Title
Craig W. Philips Takes Helm at CTI
...aluated the benefit and safety of a single dose of zevalin
patients with CD20-positive follicular lymphoma...radioimmunotherapy and is indicated as part of the zevalin
regimen for treatment of relapsed or r...patients with rituximab
refractory follicular NHL. zevalin
is also indicated, under accelerated
Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results
...ed expenses related to the creation of
commercial infrastructure to support zevalin
and fees associated with
capital structure advisory services. Net loss attr...ategy to focus resources on our late-stage development products
and growing zevalin
sales. With our commercial team now in place to support
Zevalin, we expect ...
Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
...nt payment of $10.1 million and initiated
sales, marketing, and medical affairs infrastructu... focusing resources on reaching
$15 million in net zevalin
revenues, pursuing European marketing
authorizatio...ignment completed, we can focus on
and developing our late- stage product pipeline."
Zevalin in Medical Technology
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
...ement in progression-free
survival (PFS) following zevalin
consolidation therapy for patients with
therapy over chemotherapy alone. Additionally, zevalin
consolidation did not
adversely affect the use of ...
that the median progression free survival for the zevalin
achieved a complete remission (CR)...
Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma
...igating the use of short-course CHOP-R
followed by zevalin
([90Y]-ibritumomab tiuxetan) and extended rituxima...r non-Hodgkin's lymphoma patients.
Addition of the zevalin
therapeutic regimen increased the complete
respons...ed after 3 cycles of CHOP-R alone to
82% after the zevalin
"This study adds to recently published ...
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
Food and Drug Administration (FDA) for use of zevalin
consolidation therapy based on the F...tologist/oncologists the ability to offer RIT with zevalin
patients eliminating many of the current ...ted the benefit and safety of a single infusion of zevalin
patients with CD20-positive follicular non-...
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
... September meeting to focus on use of zevalin
as consolidation therapy after remission inductio...ting with the FDA to discuss a
label expansion for zevalin
which could broaden its availability to
Therapeutics. "We continue to make progress with zevalin
on multiple fronts
with clarity on reimbursement r...
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
...peutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets zevalin
"In a high risk, elderly p...le for a registration-directed
randomized trial of zevalin
consolidation in higher risk patients with
DLBCL."...veloped myelodysplasia and two
patients died after zevalin
was given, one from a suspected brain
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
were treated with a standard dose of zevalin
administered with 2.5 to 5.0
mg/kg of MGd given fo...acyclics, and a co-author on the lymphoma study.
is a radiolabeled antibody approved for treatment of patients
with relapsed non-Hodgkin's lymphoma. zevalin
binds to tumor cells and
emits radiation to the tu...
Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
...radioimmunotherapy and is indicated as part of the zevalin
regimen for treatment of relapsed or r...eported. The most
serious adverse reactions of the zevalin
therapeutic regimen were primarily
hematologic, in...ith the degree of bone marrow
involvement prior to zevalin
therapy. Myelodysplasia or acute myelogenous
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
... was to determine the tolerability and
efficacy of zevalin
consolidation following sequential fludarabine and...y treated with Zevalin
therapy. Consolidation with zevalin
converted 12 of 14 partial remissions
(86 percent)...x cycles of therapy
indicating that treatment with zevalin
did not preclude the ability to
administer an aggr...
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
...eported. The most
serious adverse reactions of the zevalin
therapeutic regimen were primarily
hematologic, in...ith the degree of
bone marrow involvement prior to zevalin
therapy. Myelodysplasia or acute
myelogenous leuke...cent of patients (8 to 34 months
after treatment). zevalin
should only be used by health care professionals
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
...Comprehensive Cancer Center,
used a single dose of zevalin
in patients undergoing ASCT following HDC
with the...llowing the Zevalin-based regimen. The
addition of zevalin
to the BEAM regimen did not appear to add to the
t...afety and efficacy of combining a standard
dose of zevalin
(14.8 MBq/kg [0.4mCi/kg]) followed by high-dose BE...
Zevalin in Biological Technology
CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture
SEATTLE, April 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it received $6.5 million from Spectrum Pharmaceuticals, Inc. (Spectrum) in connection with the sale of its 50% interest in the Zevalin
joint venture to Spectrum for approximately $1...
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
CTI to focus on Pixantrone and OPAXIO Approval and Commercialization
SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin
joint venture to Spectrum Pharmac...
Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association
with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics,
Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008
accomplishments. CTI is seeking to obtain two new drug approvals...
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug
Administration (FDA) has accepted for filing and review, and has granted
priority review status for, the supplemental Biologics License Application
(sBLA) for ...
Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, Cell
Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a
conference call to discuss the agreement with Spectrum Pharmaceuticals of
Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
SEATTLE, Nov. 28 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of
Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will
host a conference call to discuss the agreement with Spectrum Pharmaceut...
Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
Approval would make Zevalin
only Radioimmunotherapy in U.S. to be Indicated for Use in First-Line Therapy
SEATTLE, Oct. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it has submitted a supplemental
Biologics License Appl...
Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
...losure of its Bresso, Italy pre-clinical research operation and employees associated with Zevalin. CTI recently sold its remaining 50% interest in the zevalin
joint venture to Spectrum Pharmaceuticals for approximately $16.5 million.
About Cell Therapeutics, Inc.
Headquartered in Seattl...
Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
...ion. Potential approval by end of 2009.
sales prior to the establishment of the joint vent...n in 2008.
Sold an initial 50% interest in zevalin
to a 50/50 owned joint venture with Spectrum for $...er 2008 and sold the remaining 50% interest in the zevalin
joint venture to Spectrum for approximately $16.5 ...
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
...000 patients per year would be
eligible to receive zevalin
in this setting. We assembled an experienced
sale...ss, to launch our recently approved drug FUSILEV. zevalin
complementary product that our sales ...s in the near-term and reduce our costs to develop zevalin
new growth opportunities, resulting in an incr...